COL-3 in Treating Patients With Progressive or Recurrent Brain Tumors

Phase 1/2 Completed New Approaches to Brain Tumor Therapy Consortium National Cancer Institute (NCI) · collab

Treatment

Summary

RATIONALE: COL-3 may stop the growth of brain tumors by stopping blood flow to the tumor. PURPOSE: Phase I/II trial to study the effectiveness of COL-3 in treating patients who have progressive or recurrent brain tumors following radiation therapy or chemotherapy.

Timeline

Start: 2000-07
Primary completion: —
Completion: 2006-11

Publications

Results Rudek MA, New P, Mikkelsen T, Phuphanich S, Alavi JB, Nabors LB, Piantadosi S, Fisher JD, Grossman SA. Phase I and pharmacokinetic study of COL-3 in patients with recurrent high-grade gliomas. J Neurooncol. 2011 Nov;105(2):375-81. doi: 10.1007/s11060-011-0602-9. Epub 2011 May 6.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	incyclinide	Small molecule	25 mg/m2	Oral
Subject	incyclinide	Small molecule	50 mg/m2	Oral
Subject	incyclinide	Small molecule	75 mg/m2	Oral
Subject	incyclinide	Small molecule	100 mg/m2	Oral

COL-3 in Treating Patients With Progressive or Recurrent Brain Tumors

Summary

Timeline

Publications

Drugs

Indications